secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001013762-23-004638
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BiomX appoints Eddie Williams as Class I Director to fill board vacancy
-----------------------------------------------------------------------

- Eddie Williams appointed Class I Director, term expires at 2024 annual meeting.
- Williams is independent under NYSE American rules and entered indemnification agreement.
- He currently serves on BioAtla (BCAB) board; previously Catalyst Biosciences (CBIO) board.
- Previously SVP at Novo Nordisk and VP at Novartis; over 20 years pharma experience.
- Appointment effective October 12, 2023; no arrangement with any other person.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000101376223004638/0001013762-23-004638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000101376223004638/ea186892-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-004638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer